BSE: 524663 | NSE: | Pharmaceuticals & Drugs | Small Cap
1. Is Bharat Immunologicals & Biologicals Corporation Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Bharat Immunologicals & Biologicals Corporation Ltd is a average quality company.
2. Is Bharat Immunologicals & Biologicals Corporation Ltd undervalued or overvalued?
The key valuation ratios of Bharat Immunologicals & Biologicals Corporation Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Bharat Immunologicals & Biologicals Corporation Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bharat Immunologicals & Biologicals Corporation Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||15.7%||21.6%||9.1%||-5.8%||21.6%||-9%||-13.3%||-16.1%||-35.4%||-4.2%||-|
|Value Creation Index ⓘ||0.1||0.6||-0.4||-1.4||0.6||-1.6||-2.0||-2.2||-3.5||NA||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||17.3%||-27.9%||-12.4%||-3%||-72%||140.4%||-20.1%||27.7%||-8.1%||-|
|Adj EPS ⓘ||1.1||1||0.6||-1.4||1.5||-1||-1.9||-2.4||-4.3||-2.1||-2|
|YoY Gr. Rt. %||-||-1%||-45.2%||-352.6%||NA||-166.9%||NA||NA||NA||NA||-|
|BVPS (₹) ⓘ||9.7||9.2||9.6||8.1||9.7||8.7||7.1||4.7||0.6||-1.5||-4.4|
|Adj Net Profit ⓘ||4.5||4.5||2.5||-6.2||6.4||-4.3||-8.1||-10.3||-18.4||-9.1||-9|
|Cash Flow from Ops. ⓘ||31.4||-11.9||7.8||-9.4||-17||2.5||-32.1||34.1||11.8||-42.1||-|
|Debt/CF from Ops. ⓘ||0||0.1||-1.1||-1||0||0||-1||0.1||2.3||-1.9||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||-208.1%||-207.4%||NA||NA|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||12.9||11||6||-16.3||16.6||-10.8||-23.7||-40.3||-67.4||-13.1||68.6|
|Op. Profit Mgn % ⓘ||5.4||5.9||3.2||-3.2||10.3||-22.8||-11.1||-15.6||-24.5||-6.3||-11.6|
|Net Profit Mgn % ⓘ||2.6||2.2||1.7||-4.9||5.2||-12.3||-9.7||-15.4||-21.5||-11.6||-11.2|
|Debt to Equity ⓘ||0||-0||-0.2||0.3||0||0||1.1||0.2||11.6||-12.2||-|
|Working Cap Days ⓘ||88||87||130||119||74||159||267||541||285||233||0|
|Cash Conv. Cycle ⓘ||21||6||38||55||46||125||153||250||53||84||0|
Return on Equity has increased versus last 3 years average to 68.60%
Sales growth has been subdued in last 3 years -2.14%
Sales growth is not so good in last 4 quarters at -37.47%
|TTM EPS (₹)||-2||-|
|TTM Sales (₹ Cr.)||78.4||-|
|BVPS (₹.) ⓘ||-4.4||-|
|Reserves (₹ Cr.) ⓘ||-62||-|
|From the Market|
|52 Week Low / High (₹)||20.50 / 51.80|
|All Time Low / High (₹)||0.25 / 94.50|
|Market Cap (₹ Cr.)||95.8|
|Equity (₹ Cr.)||43.2|
|Face Value (₹)||10|
|Industry PE ⓘ||36.2|
Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India. BIBCOL was established as a Public Sector Unit in 1989, with the aim to achieve self sufficiency for the nation with respect to production and supply of high quality polio vaccine, a dream project of the Former Prime Minister Late Rajiv Gandhi.
BIBCOLâ€™s principal mission is to save the lives of millions of children from avoidable disability, through polio vaccination. Since its inception, it has contributed significantly to the eradication of Poliomyelitis in the country through the National Immunization Program. BIBCOL is the pioneer in the field of polio vaccines, capturing 60% of total market share in India. The company has achieved a turnover of Rs.30.53 crores during the fiscal year 2005-2006 and earned a net profit of Rs.88.08 Lakhs. Based on the performance of the company and its world class WHO-cGMP certified infrastructure, highly skilled manpower and constant support from DBT, Government of India, BIBCOL is one among the top 20 Biotech companies in India, as revealed by recent market surveys.
Business area of the company:
The Company's principal activity is to manufacture and supply of oral polio vaccine. It supplies oral polio vaccine to Government of India. Its plant is located in Bulandshahr, Uttar Pradesh.
The live oral polio vaccine (OPV) is a trivalent vaccine containing suspensions of type 1,2 and 3 attenuated poliomyelitis viruses (Sabin strains) prepared in primary moneky kidney cell culture. Each dose contains Poliovirus type 1 = 106.0Poliovirus type 2 = 105.0Poliovirus type 3 = 105.8The vaccine contains stabilizers and traces of antibiotics.Doses: 0.1 ml (two drops)Packing Size: 3 ml vial contains 20 doses of OPVStorage: Vaccine is potent if stored at -20oC for 2 years
The trivalent OPV manufactured by BIBCOL is of excellent quality and complies with the GMP requirements of Shedule M of Drugs & Cosmetics Act of Government of India.